James E Foley

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. pmc Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial
    J E Foley
    Novartis Pharmaceutical Cooperation, Clinical Research and Development, One Health Plaza, East Hanover, NJ 07936, USA
    Diabetologia 54:1985-91. 2011
  2. pmc Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience
    James E Foley
    Clinical Research and Development, Novartis Pharmaceutical Corporation, East Hanover, NJ 07936, USA
    Vasc Health Risk Manag 6:541-8. 2010
  3. doi request reprint Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes
    J E Foley
    Clinical Research and Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
    Horm Metab Res 41:905-9. 2009
  4. doi request reprint Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes
    J E Foley
    Novartis Pharmaceutical Corporation, One Health Plaza, East Hanover, NJ 07936, USA
    Horm Metab Res 40:727-30. 2008
  5. pmc Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment
    Valentina Lukashevich
    Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936 1080, USA
    Vasc Health Risk Manag 9:21-8. 2013
  6. pmc Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies
    Anja Schweizer
    Novartis Pharma AG, Basel, Switzerland
    Vasc Health Risk Manag 7:49-57. 2011
  7. ncbi request reprint Vildagliptin does not affect C-peptide clearance in patients with type 2 diabetes
    Yan ling He
    Arkansas Research, Little Rock, USA
    J Clin Pharmacol 47:127-31. 2007
  8. ncbi request reprint Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT
    Yan ling He
    DMSc, Exploratory Development, Novartis Institutes of Biomedical Research Inc, 400 Technology Square, Building 605, Rm 811, Cambridge, MA 02139 3584, USA
    J Clin Pharmacol 47:633-41. 2007
  9. doi request reprint Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial
    C Pan
    Chinese PLA General Hospital, Beijing, China
    Diabet Med 25:435-41. 2008
  10. ncbi request reprint Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes
    B Ahren
    Department of Clinical Sciences, Division of Medicine, Lund University, Lund, Sweden
    Horm Metab Res 39:826-9. 2007

Detail Information

Publications17

  1. pmc Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial
    J E Foley
    Novartis Pharmaceutical Cooperation, Clinical Research and Development, One Health Plaza, East Hanover, NJ 07936, USA
    Diabetologia 54:1985-91. 2011
    ..Here, we assessed the insulin secretory capacity in drug-naive patients with type 2 diabetes after a 52 week treatment period with vildagliptin or placebo, and again after a 12 week washout period...
  2. pmc Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience
    James E Foley
    Clinical Research and Development, Novartis Pharmaceutical Corporation, East Hanover, NJ 07936, USA
    Vasc Health Risk Manag 6:541-8. 2010
    ..Elaboration of these and other pathways could further clarify the origins of the favorable weight profile of vildagriptin...
  3. doi request reprint Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes
    J E Foley
    Clinical Research and Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
    Horm Metab Res 41:905-9. 2009
    ....
  4. doi request reprint Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes
    J E Foley
    Novartis Pharmaceutical Corporation, One Health Plaza, East Hanover, NJ 07936, USA
    Horm Metab Res 40:727-30. 2008
  5. pmc Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment
    Valentina Lukashevich
    Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936 1080, USA
    Vasc Health Risk Manag 9:21-8. 2013
    ..73 m(2)) and longstanding type 2 diabetes not adequately controlled with insulin therapy, which is a difficult-to-treat population, with limited therapeutic options and a high susceptibility to hypoglycemia...
  6. pmc Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies
    Anja Schweizer
    Novartis Pharma AG, Basel, Switzerland
    Vasc Health Risk Manag 7:49-57. 2011
    ..The aim of this paper is therefore to assess the general safety and tolerability, including incidences of the most common adverse events (AEs), of vildagliptin based on a large pooled database of Phase II and III clinical trials...
  7. ncbi request reprint Vildagliptin does not affect C-peptide clearance in patients with type 2 diabetes
    Yan ling He
    Arkansas Research, Little Rock, USA
    J Clin Pharmacol 47:127-31. 2007
  8. ncbi request reprint Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT
    Yan ling He
    DMSc, Exploratory Development, Novartis Institutes of Biomedical Research Inc, 400 Technology Square, Building 605, Rm 811, Cambridge, MA 02139 3584, USA
    J Clin Pharmacol 47:633-41. 2007
    ..Unlike findings during mixed-meal challenges, vildagliptin increases plasma insulin levels during oral glucose tolerance tests in patients with type 2 diabetes mellitus...
  9. doi request reprint Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial
    C Pan
    Chinese PLA General Hospital, Beijing, China
    Diabet Med 25:435-41. 2008
    ..To compare the efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor, vildagliptin, with the alpha glucosidase inhibitor, acarbose, in drug-naive patients with Type 2 diabetes...
  10. ncbi request reprint Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes
    B Ahren
    Department of Clinical Sciences, Division of Medicine, Lund University, Lund, Sweden
    Horm Metab Res 39:826-9. 2007
    ..023) and postprandially (p=0.004). In conclusion, a more efficient B-cell insulin processing provides further evidence that vildagliptin treatment ameliorates abnormal B-cell function in patients with type 2 diabetes...
  11. ncbi request reprint Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes
    A Schweizer
    Novartis Pharma AG, Basel, Switzerland
    Diabet Med 24:955-61. 2007
    ..To evaluate the ability of vildagliptin and metformin to sustain reductions in HbA(1c) over a 1-year treatment period in drug-naïve patients with Type 2 diabetes (Type 2 DM)...
  12. ncbi request reprint Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study
    S Dejager
    Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA
    Horm Metab Res 39:218-23. 2007
    ..2% of patients in any treatment group reported mild hypoglycemia. In conclusion, vildagliptin monotherapy decreases HbA1c in drug-naïve patients without weight gain and is well tolerated with minimal hypoglycemia...
  13. ncbi request reprint Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
    N Matikainen
    Division of Cardiology, Department of Medicine, Helsinki University Central Hospital and Biomedicum, Helsinki, Finland
    Diabetologia 49:2049-57. 2006
    ..We assessed the effects of vildagliptin, a novel dipeptidyl peptidase IV inhibitor, on postprandial lipid and lipoprotein metabolism in patients with type 2 diabetes...
  14. ncbi request reprint Alpha cell function in health and disease: influence of glucagon-like peptide-1
    B E Dunning
    PharmaWrite, LLC, Princeton, NJ, USA
    Diabetologia 48:1700-13. 2005
    ..Therapeutic approaches based around GLP-1 have the potential to improve both alpha cell and beta cell function, and could be of benefit in patients with a broad range of metabolic disorders...
  15. ncbi request reprint Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes
    A Mari
    National Research Center, Institute of Biomedical Engineering, Corso Stati Uniti 4, 35127 Padova, Italy
    J Clin Endocrinol Metab 90:4888-94. 2005
    ....
  16. ncbi request reprint Pharmacologic restoration of the early insulin response in pre-diabetic monkeys controls mealtime glucose excursions without peripheral hyperinsulinaemia
    B E Dunning
    Novartis Pharmaceuticals Corporation, 13550 A Drive North, Ceresco, MI 49033, USA
    Diabetologia 46:M22-9. 2003
    ....
  17. ncbi request reprint Subcutaneous abdominal adipocyte size, a predictor of type 2 diabetes, is linked to chromosome 1q21--q23 and is associated with a common polymorphism in LMNA in Pima Indians
    C Weyer
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 4212 N 16th Street, Phoenix, Arizona 85016, USA
    Mol Genet Metab 72:231-8. 2001
    ..c. abd. AS can be attributed to familial factors and that genetic variation in LMNA might not only underlie rare cases of FPLD, but may also contribute to variation in adipocyte size in the general population...